

# Index

Note: page numbers in *italics* refer to figures and tables

- advanced combat helmet (ACH) 38–39
- age-at-injury, animal models 127–128
- age-dependent outcomes of TBI
  - animal models 127–128
  - children 126–127
  - lateral fluid percussion injury rodent model 117
- ageing population *see* elderly people
- airbags, road traffic injury prevention 7
- alcohol consumption/intoxication
  - neurotrauma in low- and middle-income countries 24–25
  - road traffic injuries 6, 7
  - severe TBI 105
- amantadine hydrochloride 126
- American Spinal Injury Association (ASIA)
  - Impairment Scale 216–217, 232
  - severity of injury 224
- International Standards for Neurological Classification of Spinal Cord Injury 232
- outcomes 256
- amyloid precursor protein (APP)
  - interventional therapy in impact-acceleration model 120
  - traumatic axonal injury 129, 147–148
- anal sphincter reflex, animal models of spinal cord injury 257–258
- animal models 114–122
  - axonal injury 140, 139–140, 143, 267
  - childhood TBI 127–132
    - limitations of using immature animals 132
  - clinical aspect selection 122
  - diffuse models 121
  - exercise-induced BDNF production 295
  - gender response to TBI 117, 122
  - hemorrhagic lesions 121
  - hypoxia 122
  - large animals 114, 119–121
    - controlled cortical impact 120
    - fluid percussion injury 119–120
    - impact-acceleration 120
  - inertial acceleration injury 120–121
    - spinal cord injury 253
  - locomotor training 306
  - multiple model use 121
  - NMDA receptor agonists 172–173
  - NMDA receptor antagonists 170–171, 175
    - deleterious effects 172
  - NMDA receptor dynamic changes 173–174
  - non-human primate spinal cord injury 260
  - plasticity 184
    - childhood 131–132
  - rodent 114–119, 121–122
    - closed head injury 116, 115–116
    - controlled cortical impact 118
    - cryogenic lesion 115
    - fluid percussion injury 117, 116–117, 118
    - impact-acceleration 118–119
    - optic nerve injury 115
    - spinal cord injury 253
  - species differences 121–122
  - spinal cord injury 252–260
    - autonomic function 257–258
    - behavioral tests 257
    - challenges 253–260
    - complete transection 253–254
    - compression lesion 256
    - contusion lesion 255, 256
    - decompression surgery 243–244
    - forelimb function 258
    - gray matter regions 259
    - hand function 258
    - hemisection 254–255
    - historical aspects 253
    - injury severity 259
    - large animals 253
    - lesion making 255–256
    - lesion paradigms 254
    - lesion type 253–256
    - locomotion 256–257
    - motor function 256–257
    - multiple models 259–260
    - nociception 259
    - non-human primates 260
    - outcome measures
    - pain measurement 259
    - rodent 253
    - sensation measurement 259
    - therapeutic hypothermia 314, 315–317
    - thoracic injury 256–257
    - training therapy 295–296
    - visceral function 257–258
  - anti-inflammatory drugs, cerebral inflammation treatment 164
  - anxiety, mild TBI 45–46
  - ApoE epsilon 4 allele, TBI vulnerability 12
  - apoptosis
    - animal models of childhood TBI 128–129
    - spinal cord injury 280–281
    - neurons 280
    - oligodendrocytes 266, 267, 280–281
  - Arbeitsgemeinschaft für Osteosynthese (AO) classification 233
  - thoraco-lumbar vertebral fractures 234
  - assault, traumatic brain injury 9
  - astrocytes
    - activation 157
    - axon growth regulation 276
    - cerebral inflammation 157
    - function 276–277
    - generation by neural stem cells 283
    - glial scar formation 281
    - historical aspects 276
    - myelination promotion 276
    - neural progenitor cell differentiation 293
    - species differences 277
    - spinal cord injury 276–277
  - astrogliosis 157–158
    - closed head injury model 116
  - Atlanto-occipital dislocation, treatment 234–235
  - atlas fractures, treatment 235
  - attention deficit, mild TBI 48

Cambridge University Press

978-1-107-53471-1 - Traumatic Brain and Spinal Cord Injury: Challenges and Developments

Edited by Cristina Morganti-Kossmann, Ramesh Raghupathi and Andrew Maas

Index

[More information](#)

## Index

- autologous bone marrow cell implantation 284–285
- autonomic dysreflexia 258
- autonomic function, animal models of spinal cord injury 257–258
- axis fractures, treatment 235
- axolemma permeability 143–144
- axon(s)
  - demyelination 255, 264
  - growth 264
    - promotion 266–267
    - regulation 276
  - microtubules 146–147
  - myelin/myelination 145
  - NgR1 mediated degeneration 267
  - proteases 148
  - regeneration 264
    - inhibition by glial scar 281
    - inhibitors 264
    - macrophages 275–276
    - Schwann cells 285
  - regrowth inhibition
    - chondroitin sulfate proteoglycan 264
    - molecular mechanisms 265–266
    - Nogo receptor signaling 267–268
  - swelling in traumatic axonal injury 143, 147–148
  - unmyelinated 145
- axonal guidance molecules 264
- axonal injury
  - pathophysiology 266–267
  - see also* diffuse axonal injury (DAI); traumatic axonal injury (TAI)
- axonal transport 146–147
- Basso-Beattie-Bresnahan (BBB) locomotor rating scale 256, 314
- behavioral deficits, impact-acceleration model 119
- bicycle riding 5, 6
  - helmet wearing 8, 10
- biocompatible implants, stem cell therapy combination 288–289
- biofouling, microdialysis 88
- biomarkers 82, 108, 103–108, 110
  - assays 109
  - blast injury 36–38
  - brain metabolism monitoring 75–76
  - cerebral ischemia 83
  - clinical validation 110
  - continuous flow-through ELISA 76
  - diagnostic platform development 109–110
  - events following TBI 109
  - microdialysis 85–86
  - mild TBI 106–107
  - moderate TBI 106–107
  - need for 103
- neurointensive care 85–86
  - protein 107–108
  - severe traumatic brain injury 105
- bladder function, animal models of spinal cord injury 257
- blast injury 30
  - advanced combat helmet 38–39
  - biomarkers 36–38
  - body armor 31
  - classification 32, 33, 34
  - clinical signs 37
  - clinical spectrum 34, 32–34
  - definition 32
  - historical aspects 30–31
  - improvised explosive devices 31
  - mechanisms 31
  - mild 32, 33
  - moderate 33, 32–33
  - neuroimaging 32, 37–38, 63
  - personal protective equipment 38–39
  - prevalence amongst military personnel 31–32
  - severe 33, 33–34
  - traumatic axonal injury 38
  - traumatic brain injury 9
  - tympanic membrane 34, 37
  - vasospasm 38
- blood/blood products, imaging 55–56
- blood–brain barrier (BBB) disruption
  - closed head injury model 116
  - fluid percussion injury model 119–120
- body armor, blast injury 31
- body-weight support (BWS) treadmill training 305, 308
- bone marrow stem cells (BMSC) 283
  - autologous implantation 284–285
- bone morphogenetic proteins (BMPs) 277
- boxing 62
- brain infarction, parenchymal damage 69
- brain injury, secondary 205
- brain metabolism monitoring 67–77
  - brain substrate delivery 69–73
  - functional monitoring 73–75
  - future neuroscience ICU design 77
  - glucose levels 84–85
  - industry input 77
  - insulin levels 84–85
  - low molecular weight cut-off microdialysis 83
  - methods 69–73
  - new technologies 75–77
- brain oximetry, near-infrared spectroscopy 71–72
- brain tract fibers, regeneration 310–311
- brain-derived neurotrophic factor (BDNF)
  - animal models 295
  - cortical plasticity 186
  - endogenous production 295
  - inhibition 176
  - microglial 156–157
  - NMDA receptor stimulation 176
- calcium
  - animal models of childhood TBI 130
  - homeostasis in traumatic axonal injury 144–145
- calcium-ATPase pump, traumatic axonal injury 144
- calpain(s) 129
  - traumatic axonal injury 148
- calpain inhibitors 149, 150
- carbon nanotubes 76–77
- caspases
  - activation 128–129
    - spinal cord injury 281
  - traumatic axonal injury 148
- CCL2 chemokine
  - cerebral inflammation 162–163
- CCR2 chemokine receptor 159
- cell death
  - animal models of childhood TBI 128–129
  - macrophage-induced 275–276
  - see also* apoptosis
- cell transplantation
  - macrophages
    - activated 322
    - autologous 281
    - spinal cord injury 280–289
    - clinical trials 325
- central cord syndrome 231
- central nervous system (CNS) injury 275
  - regenerative capacity 264
- central pattern generator (CPG) 294–295, 305–306
  - human spinal 307, 327
  - modulators 296
- cerebral blood flow (CBF)
  - animal models of childhood TBI 129–130
  - children 126
  - measurement 71
- cerebral hypoperfusion, animal models of childhood TBI 130
- cerebral inflammation 155–165
  - anti-inflammatory drugs 164
  - astrocytes 157
  - astrogliosis 157–158
  - CCL2 chemokine 162–163
  - chemokine inhibitors 164
  - chemokines 162–164

Cambridge University Press

978-1-107-53471-1 - Traumatic Brain and Spinal Cord Injury: Challenges and Developments

Edited by Cristina Morganti-Kossmann, Ramesh Raghupathi and Andrew Maas

Index

[More information](#)

## Index

- cerebral inflammation (*cont.*)  
 circulating monocytes 159  
 CXCR2 chemokine receptor 163–164  
 glial scar 157–158  
 IL-1 $\beta$  161  
 IL-6 161–162  
 IL-10 162  
 immunosuppressive drugs 164  
 inflammatory cytokines 160–162  
 macrophages 156, 160, 158–160, 164  
 microglia 156, 155–156, 157  
 neutrophils 156, 158, 163  
 therapeutic targeting 164  
 tumor necrosis factor 161
- cerebral ischemia  
 biomarkers 83  
 hyperglycemia 84–85  
 microdialysis critical levels 84  
 microdialysis markers 83
- cerebral metabolism, animal models of  
 childhood TBI 130–131
- cerebral microdialysis *see* microdialysis
- Cerebral Oximeter 72
- cerebral oxygenation monitoring  
 70–71, 95–96
- cerebral perfusion pressure (CPP)  
 children with therapeutic hypothermia 98  
 fluid percussion injury large animal model 119–120  
 maintenance 68
- cervical spine injuries 224  
 lower 233–234  
 anterior fusion 235  
 decompressive surgery 235  
 facet dislocation 236–237  
 imaging 235  
 incomplete tetraplegia 236, 235–236  
 treatment 235–237
- upper 232–233  
 Atlanto-occipital dislocation 234–235  
 atlas fracture treatment 235  
 axis fracture treatment 235  
 multiple fracture treatment 235  
 treatment 234–235
- Cethrin 325
- chemokine(s) 162–164
- chemokine inhibitors 164
- child safety seats 8
- children 126–132  
 age-dependent outcomes 126–127  
 amantadine hydrochloride therapy 126  
 animal models of TBI 127–132  
 cell death 128–129  
 cerebral blood flow 129–130
- cerebral metabolism 130–131
- cognitive function 127–128
- glutamate receptors 129
- histological alterations 128
- limitations of using immature animals 132
- neurodegeneration 128–129
- neurofilament compaction 129
- oxidative damage 131
- plasticity 131–132  
 traumatic axonal injury 129
- cerebral blood flow 126
- cerebral metabolism after TBI  
 99–100
- diffuse brain swelling 126
- dopaminergic activity 126
- energy expenditure after TBI  
 92–94
- falls 8
- glucose metabolism after TBI 95
- hyperglycemia 95, 99
- ketone uptake 95, 99
- measured energy expenditure 93
- mitochondrial dysfunction 126
- neuroimaging 62
- neurointensive care 126
- non-accidental injury 10
- nutrition after TBI 92–94
- outcomes 126
- PbO<sub>2</sub> 96–97, 99
- road traffic injuries 10
- therapeutic hypothermia 98–100
- tight glucose control 99
- traumatic brain injury  
 low- and middle-income countries 22–23  
 outcomes 92  
 prevention 9–10
- choline 60–61
- chondroitin sulfate proteoglycan (CSPG) 187, 255, 264  
 astrocyte-derived 264, 276  
 axonal growth inhibition 264  
 digestion 297, 325
- chondroitinase 297, 325  
 lithium chloride effects 325
- chondroitinase ABC (ChABC)  
 298–300
- clinical trials 192–203  
 adaptive randomization 195  
 ChinaSCINet 329, 328–329  
 clinical benefit proving in TBI 192–194  
 clinical outcomes 193  
 comparative effectiveness analysis 202, 201–202  
 covariate adjustment 197, 198, 200, 200  
 Cox regression 198
- data collection standardization  
 200–201
- DECRA trial 206
- enrollment criteria 195, 197, 196–198
- heterogeneity  
 covariate adjustment 198  
 imbalance risk 194–195  
 reduction 197  
 sample size calculations 195–196
- IMPACT studies 194–195, 198  
 clinical trial design/analysis improvement 194  
 coding of data elements 201  
 data collection 200
- linear regression 198
- logistic regression 198
- mega-trials 195
- minimization 195
- NMDA receptor antagonists  
 171–172, 175  
 detrimental effects 175
- odds ratio 199
- ordinal analysis 200
- outcome 199  
 predictive factors 198
- Phase I 192, 192  
 erythropoietin treatment 211–212
- Phase II 192, 192
- Phase III 192, 192  
 therapeutic hypothermia 210
- Phase IV 192, 192
- primary efficacy analysis 199–200
- prognostic analysis 198
- prognostic risk 196, 197–199
- prognostic targeting 197, 197–198
- proportional odds model 199, 200
- randomization 195
- relative study duration 196–197, 197
- sample size 194–196
- sliding dichotomy approach 199, 200
- spinal cord injury 322–329  
 activated macrophage transplantation 322  
 decompressive surgery 246  
 neuroprotective therapies 322–324  
 neuroreparative therapies 322  
 regenerative therapies 322  
 rehabilitation 322, 325–327  
 therapeutic hypothermia 317–319  
 training therapy 325–327
- study efficiency 196–198
- systems biology 202
- therapeutic hypothermia 208, 208–210  
 spinal cord injury 317–319
- closed head injury rodent model  
 NMDA receptor antagonists 170–171

- TBI 116, 115–116  
 traumatic axonal injury 141–142  
 cognitive behavioral therapy (CBT), mild traumatic brain injury 49  
 cognitive decline, traumatic brain injury 3  
 cognitive function, children 127–128  
 collapsin response mediator protein-2 (CRMP-2) 265, 266  
 comparative effectiveness research (CER) 202, 201–202  
 compensation seeking, mild traumatic brain injury 46  
 computed tomography (CT) 54  
 blast injury 32, 37  
 diagnostic 104  
 computed tomography angiography (CTA), blast injury 38  
 concussion  
 evaluation 34–35  
 post-concussional symptoms 44  
 continuing 44–46, 48  
 constraint-induced movement therapy (CIMT) 182–184  
 controlled cortical impact model  
 cortical plasticity 187–188  
 hippocampal neurogenesis following TBI 186  
 large animal 120  
 NMDA receptor antagonists 171  
 rodent 118  
 traumatic axonal injury 140  
 contusion lesion, animal models  
 childhood TBI 128–129  
 spinal cord injury 255, 256  
 cortex  
 neural restructuring after lesions 183  
 plasticity 181–184, 186–188  
 functional 186–187  
 inhibitors 187  
 structural 188, 187–188  
 primary motor 182  
 cortical spreading depression (CSD) 74–75  
*see also* spreading depolarization (SD)  
 corticospinal tract (CST) fibers, sprouting/regeneration 266  
 corticosteroids *see* glucocorticoids  
 CPP NMDA receptor antagonist, animal studies 171, 172  
 craniectomy, lateral 207  
 craniocervical fusion 235  
 craniotomy, hinged 207  
 creatinine 60–61  
 critical brain ischemia, reversal 68  
 cryogenic lesion rodent model 115  
 c-Tau biomarker 37  
 CX3CL1 chemokine 162  
 CX3CR1 chemokine receptor 162  
 production by circulating monocytes 159  
 CXCL1 chemokine 163  
 CXCL8 chemokine 158, 163, 164  
 CXCR2 chemokine receptor 163–164  
 cyclo-oxygenase 2 (COX-2), animal models of childhood TBI 131  
 cyclosporin A, traumatic axonal injury 149, 150  
 cytokines  
 inflammatory in cerebral inflammation 160–162  
 microglial 156  
 D-CCP-ene, clinical trials 171–172  
 D-cycloserine (DCS) 176  
 animal models 172–173  
 decompressive craniectomy 205–207  
 decompressive surgery in spinal cord injury  
 8-hour time window 246  
 24-hour time window 245, 246  
 48-hour time window 246  
 72-hour time window 245–246  
 clinical evidence 244–246  
 clinical research 246  
 preclinical evidence 243–244  
 radiographic criteria 246–248  
 therapeutic window 245–246  
 extension with hypothermia 316–317  
 DECRA trial 206  
 decompressive craniectomy brain injury mechanisms 206–207  
 Defense Veterans Brain Injury Center TBI Screening Tool 35  
 demyelination  
 axons 255, 264  
 macrophage-induced 275  
 dendrites  
 arborization 187  
 pruning 183  
 depression  
 mild traumatic brain injury 48, 49  
 symptoms 36  
 traumatic brain injury 36  
 diffuse axonal injury (DAI) 138  
 neuroimaging 138  
 treatment 148–149  
 diffuse brain atrophy, infants 126  
 diffuse brain injury, animal models of childhood TBI 128  
 diffuse brain swelling, children 126  
 diffusion tensor imaging (DTI) 57, 56–57, 59  
 apparent diffusion coefficient 58  
 blast injury 38, 63  
 connectivity measurement 59–60  
 disability-adjusted life-years (DALYs), neurotrauma 17  
 dopaminergic activity, children 126  
 economic costs  
 traumatic brain injury 3, 103  
 low- and middle-income countries 26  
 traumatic spinal cord injury 222  
 elderly people  
 falls 8  
 traumatic spinal cord injury 216, 222  
 subdural hematoma 12  
 traumatic brain injury 11, 11–12  
 low- and middle-income countries 23  
 traumatic spinal cord injury 216, 222  
 electrocorticography (ECoG) 75, 74–75  
 electroencephalogram (EEG), seizure monitoring 73–74  
 electromyography (EMG), spinal cord injury 307  
 embryonic stem cells 282  
 endothelial monocyte-activating polypeptide II precursor (EMAPII) 108  
 energy expenditure after TBI 92–94  
 enzyme-linked immunosorbent assay (ELISA) 76  
 ephrin(s) 264, 266  
 astrocyte-derived 276  
 ephrin-B3 265  
 epidural electrical stimulation 327  
 epilepsy, traumatic brain injury 35–36  
 erythropoietin 211–212  
 cerebral inflammation treatment 164  
 treatment of TBI 210–212  
 excitatory amino acids (EAA) 73  
 excitotoxicity  
 glutamate-induced 170, 174–175  
 low molecular weight cut-off microdialysis 85–86  
 exercise therapy  
 cellular transplant combination 298  
 pharmacotherapy combination 299  
 spinal cord injury 294–296, 298, 299, 327  
 facet dislocation 236–237  
 falls  
 prevention 222  
 traumatic brain injury 8, 11–12  
 India 21

Cambridge University Press

978-1-107-53471-1 - Traumatic Brain and Spinal Cord Injury: Challenges and Developments

Edited by Cristina Morganti-Kossmann, Ramesh Raghupathi and Andrew Maas

Index

[More information](#)

## Index

- falls (*cont.*)  
  low- and middle-income countries 23, 27  
  Papua New Guinea 21  
  traumatic spinal cord injury 216, 222  
    characteristics 224  
    elderly people 222
- Fas ligands 281
- fiberoptic ICP monitors 69
- fibroblasts, genetically modified 294
- firearms 9
- FK506, traumatic axonal injury 149, 150
- fluid percussion injury model  
  hippocampal neurogenesis following TBI 186  
  large animal 119–120  
  NMDA receptor antagonists 170, 171  
  rodent 117, 116–117, 118  
  traumatic axonal injury 141, 140–141
- fluid-coupled ICP monitors 69
- flumazenil PET 62
- forelimb function, animal models of spinal cord injury 258
- fractalkine *see* CX3CL1 chemokine
- gait  
  neuronal mechanisms 306  
  standardized analysis 310  
  *see also* locomotion; walking
- gait training, robotic 308–310
- gangliosides 324–325
- GAP43 187
- gender response to TBI  
  animal models 122  
  lateral fluid percussion injury rodent model 117
- Glasgow Coma Scale (GCS) 2, 67–69  
  functional monitoring 73  
  inaccuracy in severe TBI 105  
  limitations 104
- Glasgow Outcome Scale (GOS) 193, 199
- glial fibrillary acidic protein (GFAP) 37, 157, 158
- glial scar 157–158, 276  
  astrocytes 281  
  proliferation 276
- axonal regeneration inhibition 281
- olfactory ensheathing glia implantation 285
- glucocorticoids  
  cerebral inflammation treatment 164  
  spinal cord injury 323  
  *see also* methylprednisolone
- glucose  
  animal models of childhood TBI 130–131  
  brain level management 84–85  
  serum concentration measurement 95
- glucose metabolism after TBI 94–95
- glutamate  
  binding site 169  
  biomarker 85–86  
  changes after brain injury 170  
  extracellular 170  
  stroke patients 174–175
- glutamate antagonists, clinical trials 171, 174–176
- glutamate receptors 169  
  animal models of childhood TBI 129  
  over-stimulation in TBI 170
- glutathione peroxidase 131
- glycemic control, neurointensive care 85
- glycerol 73  
  biomarker 85–86
- glycolysis, animal models of childhood TBI 130–131
- gray matter injury  
  animal models of spinal cord injury 259  
  mechanisms 55
- gunshot wounds 9
- Haddon matrix 26, 27
- hand function, animal models of spinal cord injury 258
- Hangman's fracture, treatment 235
- Harris/Benedict equation 92–93, 93
- helmets  
  advanced combat helmet 38–39  
  occupational injury prevention 9  
  road traffic injury prevention 7–8, 10  
  sports injury prevention 8–9
- high-income countries (HICs), TBI burden 19
- high mobility group protein-1 (HMG-1) 186
- hippocampus  
  dendritic arborization  
  matrix metalloproteinase 3  
  expression 185–186  
  neurogenesis following TBI 186  
  plasticity following TBI 184–186
- homotopic cortex 181
- HSP27 295
- human spinal cord injury syndrome 252–253
- hydrogels, biocompatible implants 288–289
- 5-hydroxytryptamine (5-HT) 299  
  central pattern generator  
  modulation 296
- hyperglycemia  
  cerebral ischemia 84–85
- children 95, 99  
  TBI outcomes 95
- hyperglycolysis 94–95
- animal models of childhood TBI 130
- hyperthermia, spinal cord injury 314–315
- hypotension, spinal cord injury 244
- hypothermia, therapeutic  
  spinal cord injury 314  
  animal models 314, 315–317  
  cervical 316, 318  
  clinical studies 317–319  
  complications 319  
  functional outcome 318, 318, 319  
  injury mechanisms 316  
  locomotor recovery 316  
  surgical intervention therapeutic window extension 316–317  
  systemic cooling strategies 316
- ventral motor neuron  
  preservation 317
- systemic 316
- TBI 92, 97–99, 207–210  
  adverse effects 210  
  applications 99  
  children 98–100  
  Clifton study 208–210  
  clinical studies 208, 208–210  
  complications 210  
  early 98–99  
  equipment 209  
  experimental models 207–208  
  intracranial pressure control 209  
  meta-analyses 208, 210  
  multi-center Phase III trials 210  
  therapeutic window 208  
  traumatic axonal injury 149, 150
- hypoxia  
  animal models 122  
  impact-acceleration model 119  
  spinal cord injury 244
- hypoxic-ischemic injury,  
  neuroimaging in children 62
- immune reactions  
  innate immune response 272  
  neutrophils 272–274  
  microglia 155–157  
  spinal cord injury 281
- immunosuppressive drugs  
  cerebral inflammation 164  
  traumatic axonal injury 149, 150
- IMPACT studies 194, 195, 198  
  clinical trial design/analysis  
  improvement 194  
  coding of data elements 201  
  data collection 200
- impact-acceleration model  
  large animal 120  
  rodent 118–119



- improvised explosive devices (IEDs) 31  
 IN-1 monoclonal antibody 267–268, 325  
 induced pluripotent stem cells (iPSC) 286  
 inertial acceleration injury model 120–121  
 infants 126–127  
 inflammation  
   glial scar 276  
   spinal cord injury 272–277, 324  
     astrocytes 276–277  
     macrophages 274–276, 277  
     neutrophils 272–274  
   *see also* cerebral inflammation  
 information processing, mild TBI 48  
 innate immune response 272  
   neutrophils 272–274  
 insulin, brain level management 84–85  
 insulin therapy, tight glucose control 95  
 intercellular adhesion molecule 1 (ICAM-1) 274  
 intercellular adhesion molecule 1, soluble (sICAM-1) 162  
 interleukin 1 $\beta$  (IL-1 $\beta$ ) 161  
 interleukin 6 (IL-6) 161–162  
 interleukin 8 (IL-8) *see* CXCL8  
   chemokine  
 interleukin 10 (IL-10) 162  
 intracranial pressure (ICP)  
   children with therapeutic hypothermia 98  
   control  
     secondary brain injury prevention 205–206, 207  
     therapeutic hypothermia 209  
   decompressive craniectomy 206  
   epileptiform activity 74  
   fiberoptic monitors 69  
   fluid percussion injury large animal model 119–120  
   fluid-coupled monitors 69  
   impact-acceleration model 120  
   management 69  
   monitoring 69  
   pupillary change 75  
   severe blast injury 33–34  
   therapeutic hypothermia 98  
 ion homeostasis, traumatic axonal injury 144–145  
 jugular venous oxygen saturation (SjvO<sub>2</sub>) 70  
 kainate receptors 173  
 ketone uptake in children's brains 95, 99  
 kyphoplasty 239  
 kyphosis, thoracic spine injuries 237, 238  
 lactate/creatinine ratio 130  
 lactate/pyruvate ratio 61, 73  
   epileptiform activity 74  
   ischemia marker 83  
   microdialysis 83–84  
 laser Doppler flowmetry 71  
 lateral fluid percussion injury rodent model 116–118  
 leg muscle activation 307–308, 308  
 legislation, traumatic brain injury prevention 10  
 leukocyte function-associated antigen (LFA-1) 159  
 leukocytes, migration/recruitment 162  
 LINGO-1 (LRR and Ig domain-containing Nogo receptor-interacting protein) 265  
 lithium chloride 325  
 litigation seeking, mild TBI 46  
 locomotion  
   animal models of spinal cord injury 257, 256–257  
   central pattern generator 294–295, 305–306, 327  
   modulators 296  
   evaluation 256–257  
   hindlimb 294–295  
   leg muscle activation pattern 307–308  
   neuronal basis 305–306  
   neuronal mechanisms 306  
   rehabilitation goal 305  
 locomotor pattern, spinal cord injury 307, 308  
 locomotor recovery, spinal cord injury 325–327  
 locomotor training  
   animal studies 306  
   CNS damage 307–308  
   essential cues 307–308  
   function recovery 308  
   loading 307  
   spinal cord injury 309, 305–309, 311  
   clinical trials 325–327  
 long-term depression, hippocampal plasticity 185  
 long-term potentiation  
   D-cycloserine 176  
   hippocampal plasticity 185  
 low- and middle-income countries (LMICs) 17–18  
   African countries 19–20  
   age 23  
   burden 18–19  
   children 22–23  
   China 22  
   epidemiological studies 18–19  
   gender 23  
   India 20–21  
   Nepal 22  
   neurotrauma 17–27  
   Nigeria 19–20  
   Pakistan 20  
   Papua New Guinea 21  
   prevalence 23  
   Taiwan 22  
   traumatic brain injury 17–18  
   Vietnam 21–22  
 lumbar spine injuries, treatment 239  
 Ly6C (Gr1), production by circulating monocytes 159  
 macrophages  
   autologous transplantation 281  
   axon regeneration 275–276  
   axon regrowth promotion 160  
   brain tissue damage 159  
   cell death 275–276  
   cerebral inflammation 156, 160, 158–160, 164  
   demyelination 275  
   function 274, 275–276  
   historical aspects 274–275  
   infiltration 158–159  
   M1 and M2 subsets 160, 159–160  
   neuronal toxicity 160  
   peripheral nerve repair 275  
   response onset/magnitude 275  
   species differences 276  
   spinal cord injury 274–276, 277, 285–286  
   stimulated 285–286  
   transplantation of activated 322  
 magnetic random access memory (MRAM) 76  
 magnetic resonance imaging (MRI)  
   54  
   blast injury 37  
   diagnostic 104  
   SPIO nanoparticle contrast agent 286–288  
 magnetic resonance imaging, functional (fMRI) 59–60  
 magnetic resonance spectroscopy (MRS) 60–61  
   blast injury 38  
   techniques 60  
 magnetoencephalography (MEG), blast injury 38  
 major depressive disorder, traumatic brain injury 36  
 matrix metalloproteinase 3 (MMP-3) 185–186

Cambridge University Press

978-1-107-53471-1 - Traumatic Brain and Spinal Cord Injury: Challenges and Developments

Edited by Cristina Morganti-Kossmann, Ramesh Raghupathi and Andrew Maas

Index

[More information](#)

## Index

- measured energy expenditure (MEE) 93  
 children 93  
 membrane phospholipid degradation, LMW cut-off microdialysis 85–86  
 membrane pumps, traumatic axonal injury 144  
 memory  
   hippocampal plasticity 185  
   NMDA receptor association 173  
 mesenchymal stromal cells 283–284  
   spinal cord injury 283–285  
   SPIO nanoparticle-labeled 284, 288  
 metabolic crisis following TBI 83–84  
 metabotropic glutamate receptors (mGluRs) 169  
 methylprednisolone, clinical trials in spinal cord injury 322–324  
 methylprednisolone sodium succinate 243  
 microchip technology 77  
 microdialysis 72–73, 82–88  
   biofouling 88  
   biomarkers 85–86  
   combination with global monitoring techniques 86–87  
   critical levels in cerebral ischemia 84  
   extraction efficiency 87  
   fluid balance control 87–88  
   fluid recovery 87, 88  
   glucose brain level management 84–85  
   high molecular weight cut-off 87–88  
   insulin brain level management 84–85  
   lactate/pyruvate ratio 83–84  
   low molecular weight cut-off 83–87  
     excitotoxicity 85–86  
     ischemic energy metabolic crisis following TBI 83  
     limitations 86–87  
     membrane phospholipid degradation 85–86  
     metabolic monitoring 83  
     non-ischemic energy metabolic crisis following TBI 83–84  
     oxidative stress 85–86  
   protein recovery 87  
   relative recovery 87, 88  
   role 82  
   spreading depolarization 84  
 microglia 155–157  
   activation 155–156, 281  
   function 274  
   innate immune response 272  
   spinal cord injury 274, 281  
   Wallerian degeneration 274–275  
   *see also* macrophages  
 microglial antiporter system  $X_c^-$  85  
 microprocessing 76  
 microtubule(s) 146–147  
 microtubule-associated proteins (MAPs) 146  
 mild traumatic brain injury (mTBI) 43–50  
   anxiety association 45–46  
   attention deficit 48  
   biomarkers 106–107  
   causes 43  
   cerebral changes 44  
   clinical criteria 43  
   cognitive behavioral therapy 49  
   cognitive problem management 47–48  
   compensation seeking 46  
   definition 43  
   demographic factors 45  
   depression 48, 49  
   diagnosis 43–44, 104  
   diagnostic biomarkers 107  
   diagnostic tools 104  
   genetic factors 45  
   homeopathy 47  
   information-processing problems 48  
   information provision for patients 46–47  
   initial screening 43–44  
   litigation seeking 46  
   management 46–47  
   multiple head injuries 45  
   neuroimaging 44, 107  
   neurological symptom treatment 47  
   neuronal damage 45  
   outcome 45  
   pathophysiology 44  
   pharmacological interventions 47  
   physical symptom treatment 47  
   post-concussional symptoms 44  
     continuing 44–46, 48  
   post-traumatic amnesia 43–44  
   pre-existing psychiatric disorder identification 47  
   psychological issues 48–50  
   PTSD association 45–46, 49  
   risk of repeated injury 106–107  
   sleep disorders 49  
   sports-related 50  
   symptom mastery 48–49  
 Military Acute Concussion Evaluation (MACE) 34–35  
 military personnel  
   blast injury prevalence 31–32  
   personal protective equipment 38–39  
   TBI screening 34–35  
 minocycline, cerebral inflammation treatment 164  
 mitochondrial dysfunction  
   animal models of childhood TBI 131  
   children 126  
   traumatic axonal injury 144–145  
 MK 801, animal studies 170, 172, 173  
 moderate traumatic brain injury (TBI)  
   biomarkers 106–107  
   diagnostic tools 104  
   neuroimaging 107  
   risk of repeated injury 106–107  
 monocyte(s), circulating 159  
 monocyte chemotactic protein-1 (MCP-1) *see* CCL2 chemokine  
 monosialic gangliosides (GM1) 324–325  
 motor cortex, reorganization after stroke 181  
 motorcycles  
   helmet wearing 7–8  
   legislation 10, 22  
   traumatic brain injury 5  
   Nigeria 19–20  
   Taiwan 22  
 motor training 294  
 motor vehicle injuries *see* road traffic injuries  
 movement patterns, neuronal networks 305  
 multi-frequency/-wavelength phase modulation 72  
 myelin inhibitors of neurite outgrowth, spinal cord injury 264–268  
   axonal regrowth inhibition 265–266  
   blockers 297  
   NgR1-mediated axonal degeneration 267  
   oligodendrocyte survival 266–267  
 myelin, traumatic axonal injury 145  
 myelin-associated glycoprotein (MAG) 265, 266  
   pharmacological inhibition 281  
 myelin-associated inhibitory factors (MAIF) 264–265  
   oligodendrocyte survival 266–267  
 myelination  
   astrocytes 276  
   traumatic axonal injury 145  
   *see also* demyelination  
 N-acetylaspartate (NAA) 60–61  
 Na/K ATPase pump 73  
   traumatic axonal injury 144  
 nanotechnology 76  
 nanowires 76–77  
 near-infrared spectroscopy (NIRS) 71–72  
 neocortex, plasticity following TBI 186–188  
 NEP1–40 268

Cambridge University Press

978-1-107-53471-1 - Traumatic Brain and Spinal Cord Injury: Challenges and Developments

Edited by Cristina Morganti-Kossmann, Ramesh Raghupathi and Andrew Maas

Index

[More information](#)

## Index

- nerve growth factor (NGF)  
cortical plasticity 186  
microglial 156–157  
netrins 264, 266  
neural progenitor cells 293  
neural stem cells 283  
spinal cord injury 282–283  
neurites  
myelin inhibitors of outgrowth in  
spinal cord injury 264–268  
MAIFs 264–265  
outgrowth regulation 266, 267–268  
neurodegeneration, animal models of  
childhood TBI 128–129  
neurofilaments  
compaction 129, 146  
misalignment 146  
traumatic axonal injury 145–146  
neurogenesis, hippocampal following  
TBI 186  
neuroglia *see* microglia  
neuroimaging  
blast injury 32, 37–38, 63  
children 62  
diagnostic 104  
metabolism measurement 60–62  
mild traumatic brain injury 44, 107  
moderate traumatic brain injury 107  
spinal cord compression 247  
spinal cord injury 230, 246–248  
SPIO nanoparticle contrast agent  
286–288  
sports injuries 62  
technique development 54–63  
*see also named modalities*  
neurointensive care  
children 126  
improvement 83  
neurological examination 67–69  
assessment 73  
neurological pupillary index  
(NPi) 75  
neuron(s)  
apoptosis 280  
migration regulation 266  
neurofilaments 145–146  
neuron-specific enolase (NSE)  
biomarker 37  
neuronal circuit plasticity 295  
neuronal death  
animal models of childhood TBI  
128–129  
traumatic axonal injury 148  
neuronal networks, movement  
patterns 305  
neuro-orthopedic instrumentation,  
traumatic spinal cord injury  
230  
neuroplasticity *see* plasticity  
neurotrauma, low- and middle-income  
countries 17–27  
African countries 19–20  
age 23  
alcohol consumption 24–25  
burden 18–19  
causes 24, 23–24  
China 22, 26  
control 26–27  
DALYs 17  
economic impact 26  
elderly people 23  
epidemiological studies 18–19  
falls 23, 27  
India 21  
Papua New Guinea 21  
gender 23  
incidence 17  
India 20–21, 24, 26  
nature 25  
Nepal 22  
Nigeria 19–20  
outcomes 25–26  
Pakistan 20  
Papua New Guinea 21  
pediatric 22–23  
prevalence 23  
prevention 26–27  
risk factors 25  
road traffic injuries 23  
alcohol consumption 24–25  
severity 25  
Taiwan 22, 26  
pediatric injuries 22  
trauma care 25  
Vietnam 21–22  
neurotrophic factor(s) (NTF) 292–294,  
297  
neurotrophic factor 3 (NT-3) 299  
neutrophils  
activation 158, 273  
bystander damage 273  
cerebral inflammation 156, 158, 163  
depletion 274  
historical aspects 273–274  
infiltration to damaged CNS 158  
innate immune response 272–274  
migration 273  
post-spinal cord injury  
neurodegeneration 273  
species variations 274  
nicotinamide adenine dinucleotide  
(NADH) 77  
N-methyl-D-aspartate (NMDA)  
animal models of childhood TBI 130  
fragments 37  
NR2A subunit 131  
N-methyl-D-aspartate (NMDA)  
receptor(s) 169–177  
animal models 173–174  
BDNF release 176  
blockade in recovery phase 176  
channel function 169  
dendrite pruning 183  
dynamic changes 174  
functions 176  
hyperactivation 174  
memory function 173  
oligodendrocytes 281  
subunits 173–174  
synapse pruning 183  
N-methyl-D-aspartate (NMDA)  
receptor agonists 172–173  
N-methyl-D-aspartate (NMDA)  
receptor antagonists 170, 173  
animal models 170–171, 175  
deleterious effects 172, 175  
clinical trials 171–172, 175  
competitive 171–172  
dendrite/synapse pruning  
prevention 183  
non-competitive 170–171, 172  
N-methyl-D-aspartate (NMDA)  
receptor channel pore 170  
Nogo-A 265, 266, 325  
axonal growth inhibition 267  
function-blocking antibodies 268  
high-affinity binding sites 268  
pharmacological inhibition  
267–268, 281  
Nogo receptor (NgR) signaling  
complex 265–266  
Nogo receptor 1 (NgR1) 265, 265, 297  
axonal degeneration mediation 267  
high-affinity binding sites 268  
pharmacological inhibition 267–268  
Nogo receptor 1 (310aa) ectodomain  
fused to Fc portion of IgG1  
(NgR1(310)-Fc protein) 268  
non-accidental injury  
children 10  
neuroimaging 62  
nutrition after TBI 92–94  
occupational injuries  
traumatic brain injury 9  
traumatic spinal cord injury 224  
olfactory ensheathing glia (OEG) 285,  
293–294  
oligodendrocyte(s)  
apoptosis 266–267, 280–281  
neural progenitor cell differentiation  
293  
NMDA receptors 281  
survival 266–267  
oligodendrocyte progenitor cells 282  
oligodendrocyte-myelin glycoprotein  
(OMgp) 265, 266



## Index

- oncomodulin 267
- open skull impact/impulse injury  
model, traumatic axonal injury 140–141
- optic nerve injury rodent model 115  
traumatic axonal injury 142, 267
- oxidative damage, animal models of  
childhood TBI 131
- oxidative stress  
activated microglia 156  
low molecular weight cut-off  
microdialysis 85–86  
neutrophil production of free  
radicals 158
- oxygen  
cerebral monitoring 70–71, 95–96  
device utilization 71  
metabolism after TBI 95–97
- oxygen tension, critical threshold  
values 70
- oxygenation, tissue 69–71
- $p75^{\text{NTR}}$  265–266
- pain measurement, animal models of  
spinal cord injury 259
- partial pressure of interstitial brain  
oxygen ( $\text{PbO}_2$ ) 96–97  
children 96–97, 99  
management of levels 96
- penile erection, animal models of  
spinal cord injury 257–258
- pentose phosphate pathway (PPP) 84
- peri-infarct depolarization (PID) 74
- peripheral nerve grafts, spinal cord  
injury 294
- peripheral nervous system 275
- personal protective equipment (PPE)  
38–39
- plasticity 180–188  
adult 180  
animal models of TBI 184  
childhood 131–132  
CNS lesions 307  
cortical 181–184, 186–188  
functional 186–187  
inhibitors 187  
structural 188, 187–188  
critical period 180  
dendrite pruning 183  
developmental 180  
following TBI 184–188  
hippocampal 184–186  
mechanisms 306–307  
microarray studies 184–185  
neocortical 186–188  
rehabilitation 305  
spinal cord injury  
structural 181–184  
synapse pruning 183
- poloxamer 188, traumatic axonal  
injury treatment 143–144
- poly-ADP-ribose polymerase (PARP)  
130
- poly(lactic acid-co-glycolic acid)  
(PLGA) 289
- polylysine-poly(ethylene glycol) (PEG)  
289
- polymorphonucleocyte (PMNL),  
post-traumatic hypothermia  
effects 316
- positron emission tomography (PET)  
61–62  
blast injury 37–38, 63, 63  
flumazenil 62
- Post Deployment Health Assessments  
(PDHA) 35
- post-concussional symptoms (PCS) 44  
continuing 44–46, 48
- post-traumatic amnesia (PTA) 43–44
- post-traumatic stress disorder (PTSD)  
biomarker for TBI discrimination  
36–37  
definition 35  
depression co-morbidity 36  
diagnostic criteria 35  
mild TBI association 45–46, 49  
overlap with traumatic brain injury  
30, 36  
pathophysiology 35  
preconditioning 36  
symptoms 36
- productivity loss 3
- proteases, traumatic axonal injury 148
- protein biomarkers 107–108
- $\text{PtiO}_2$  cerebral oxygenation monitoring  
70–71
- pupillometers 75
- pyruvate dehydrogenase (PDH) 131
- quantum dots 76–77
- quipazine 299
- quisqualate receptors 173
- randomized controlled trial (RCT)  
192, 327–328
- rapid stretch injury in vivo model,  
traumatic axonal injury  
142–143
- reactive oxygen species (ROS),  
microglial 156
- recreational injuries, TBI 8–9
- rehabilitation in spinal cord injury  
clinical trials 322, 325–327  
epidural electrical stimulation 327  
monitoring progress 310  
neuronal plasticity 305
- resting energy expenditure (REE)  
92–93
- retinal ganglion cells, optic nerve crush  
267
- Rho guanosine triphosphatases  
(Rho-GTPases) 265, 266
- RhoA pathway 297
- RhoA-GTP 265
- road traffic injuries  
airbags 7  
alcohol consumption 6, 7  
low- and middle-income  
countries 24–25  
child safety seats 8  
children 10  
economic cost 3  
low- and middle-income  
countries 26  
economic status of country 5–6  
helmets 7–8  
low- and middle-income countries  
23  
African countries 19–20  
China 22  
economic cost 26  
India 20–21, 24  
Nigeria 19–20  
Pakistan 20  
Papua New Guinea 21  
risk factors 25  
Taiwan 22  
Vietnam 21–22  
prevention 7–8  
low- and middle-income  
countries 26–27  
strategy effectiveness 10  
seat belts 7  
speed 7  
traumatic brain injury 4, 6, 4–6, 8  
traumatic spinal cord injury 216, 222  
characteristics 224  
trends in injuries 5–6  
robotic gait training 308–310  
rotational-acceleration injury model,  
traumatic axonal injury  
139–140
- S100 $\beta$  serum biomarker 37
- Schwann cells 285
- seat belts, road traffic injury  
prevention 7
- second impact syndrome 106–107
- secondary brain injury 205
- seizures  
cortical spreading depression  
co-occurrence 74–75  
monitoring 73–74  
traumatic brain injury 35–36  
self-harm, traumatic brain injury 9
- Selfotel, clinical trials 171
- semaphorin(s) 264, 266

- semaphorin-4D 265
- sensation measurement, animal
  - models of spinal cord injury 259
- severe traumatic brain injury (TBI)
  - accident scene management 105
  - alcohol intoxication 105
  - biomarker use 105
  - brain tissue swelling 209
  - diagnostic biomarkers 104–105, 106
  - diagnostic tools 104
  - erythropoietin clinical trial 211–212
  - Glasgow Coma Scale inaccuracy 105
- single-photon emission tomography (SPECT), blast injury 37–38
- sleep disorders, traumatic brain injury
  - 36
  - mild 49
- slits 264, 266
- social costs, traumatic spinal cord injury 222
- sodium channels, traumatic axonal injury 144
- $\alpha$ II-spectrin breakdown products 37
- spinal cord
  - antero-posterior (AP) diameter 247
  - electrical stimulation of lumbosacral cord 327
  - hemorrhage 247
  - intramedullary edema 247
  - regeneration 310–311
  - swelling 247
- spinal cord compression 231, 242
  - cervical 248, 247–248
  - definition using MRI measures 247
  - imaging 247
- spinal cord injury, traumatic
  - acute injury
    - cellular transplants 293
    - environmental modification 297
    - exercise/training 295
    - methylprednisolone treatment 323
  - age distribution 221, 221–222
  - animal models 243–244, 252–260
    - autonomic function 257–258
    - behavioral tests 257
    - challenges 253–260
    - complete transection 253–254
    - compression lesion 256
    - contusion lesion 255, 256
    - forelimb function 258
    - gray matter regions 259
    - hand function 258
    - hemisection 254–255
    - historical aspects 253
    - injury severity 259
    - large animals 253
    - lesion making 255–256
    - lesion paradigms 254
    - lesion type 253–256
    - locomotion 257, 256–257
    - motor function 256–257
    - multiple models 259–260
    - nociception 259
    - non-human primates 260
    - outcome measures 256–260
    - pain measurement 259
    - rodent 253
    - sensation measurement 259
    - thoracic injury 256–257
    - visceral function 257–258
  - apoptosis 280–281
    - neurons 280
    - oligodendrocytes 266–267, 280–281
  - associated disorders 252
  - astrocytes 276–277
  - burden 252
  - causes 223, 222–223, 224
  - cell death 280–281
  - cellular transplants 280–289, 292–294
    - activated macrophages 322
    - acute injury 293
    - autologous macrophages 281
    - chronic injury 293–294
    - clinical trials 325
    - exercise combination 298
    - pharmacotherapy combination 298, 298–299
    - subchronic injury 293
  - cervical cord 224
  - characteristics 224
  - chronic injury 292
    - cellular transplants 293–294
    - environmental modification 297
    - scar formation 297
    - training therapy 295–296
  - classification systems 232–234
    - neurological deficit 232
    - spine injuries 232–234
  - clinical trials 322–329
    - activated macrophage transplantation 322
    - cell transplantation 325
    - decompressive surgery 246
    - locomotor training 325–327
    - neuroprotective therapies 322–324
    - neuroreparative therapies 324–325
    - regenerative therapies 322, 324–325
    - rehabilitation 322, 325–327
    - therapeutic hypothermia 317–319
    - training therapy 325–327
  - complete 324
    - locomotor training 326
  - complications 252
  - contusion 315
  - definition 216–217
  - demographics 220–222
  - diagnosis 216–217
  - disease frequency measures 217–220
  - economic costs 222
  - electromyography 307
  - environmental modification 297
  - epidemiology 216–225, 252
  - etiology 223, 222–223, 224
  - exercise therapy 294–296, 327
    - cellular transplant combination 298
    - pharmacotherapy combination 299
  - falls 222
    - characteristics 224
    - elderly people 216, 222
  - features 252
  - genetically modified fibroblasts 294
  - GM1 therapy 324–325
  - healthcare 224
  - human injury syndrome 252–253
  - hyperthermia 314–315
  - hypotension 244
  - hypoxia 244
  - imaging 230, 246–248
  - immune component 281
  - incidence 219, 217–219, 219
    - prevention measures 219
    - regional differences 218, 217–218
    - temporal differences 218–219, 220
  - incomplete 224, 308, 324
  - inflammation 272–277, 324
    - astrocytes 276–277
    - macrophages 274–276, 277
    - neutrophils 272–274
  - initial assessment 230–231
    - neurological 224
  - injury types 252
  - instrumented spinal fixation
    - techniques 244
  - kyphoplasty 239
  - level 224
  - localized cord cooling 315
  - locomotor ability 308
  - locomotor pattern 307, 308
  - locomotor recovery 325–327
  - locomotor training 309, 305–309, 311
    - clinical trials 325–327
  - lumbar spine injuries 239
  - macrophages 274–276, 277
  - management priorities 231
  - microglia 274, 281
  - mortality 242

## Index

- spinal cord injury, traumatic (*cont.*)  
 motor training 294  
 myelin inhibitors of neurite outgrowth 264–268  
 blockers 297  
 neural pathway sparing 306  
 neural progenitor cells 293  
 neurological damage 229  
 neurological deficit classification 232  
 neurological recovery 247  
 neuronal plasticity  
 neuro-orthopedic instrumentation 230  
 neuroprotective agents 243, 322–324  
 neuroreparative therapies 324–325  
 neurotrophic factors 292–294, 297  
 neutrophils 272–274  
 occupational injury prevention 224  
 olfactory ensheathing glia 285, 293–294  
 pathology 242–243  
 pathophysiology 280–281  
 peripheral nerve grafts 294  
 prevalence 219–220  
 prevention measures 222–224  
 incidence 219  
 primary 243, 242–243, 280  
 prognosis 229  
 prognostic factors 247  
 regenerative therapies 322, 324–325  
 rehabilitation  
 clinical trials 322, 325–327  
 monitoring progress 310  
 neuronal plasticity 305  
 road traffic injuries 216, 222  
 characteristics 224  
 prevention 222  
 robotic gait training 308–310  
 secondary 242, 243, 243, 280–281  
 contusion lesions 255  
 mesenchymal stromal cells 284  
 secondary damage avoidance 229  
 severity 221, 224  
 sex differences 221, 222  
 signaling cascade of down stream events 243  
 social costs 222  
 spine injuries classification 232–234  
 subchronic injury  
 cellular transplants 293  
 environmental modification 297  
 exercise/training 295  
 surgical approaches 229–230  
 temperature management 314–319  
 temperature rise 314–315  
 training therapy 294–296  
 clinical trials 325–327  
 optimizing 310  
 use-dependent activity 295
- treatment 229, 242, 292–300  
 cellular transplants 292–294, 298, 298–299  
 cement injection 239  
 combination therapies 298, 297–298, 300  
 complications prevention 240  
 conservative 234–240  
 environmental modification 297  
 exercise therapy 294–296, 298, 299, 327  
 historical milestones 229–230  
 initial 230–231  
 intraoperative neuromonitoring 240  
 kyphoplasty 239  
 lower cervical spine 235–237  
 lumbar spine injuries 239  
 medical approaches 230  
 neuroprotective agents 243, 322–324  
 neuroreparative therapies 324–325  
 peri operative spinal cord injury prevention 240  
 pharmacological targets 296–297  
 pharmacotherapy with cellular transplants 298, 298–299  
 pharmacotherapy with exercise 299  
 regenerative therapies 322, 324–325  
 rehabilitation 305, 310, 322, 325–327  
 stem cell therapy 280, 281–289  
 surgical 230–231, 234–240  
 thoracic spine 237–239  
 thoraco-lumbar spine 239  
 training therapy 294–296, 310, 325–327  
 transmitter-related 296  
 transplantation/exercise/ pharmacotherapy 299–300  
 upper cervical spine 234–235  
 vertebroplasty 239  
 untreatable injury 229  
 vertebroplasty 239  
*see also* cervical spine injuries; decompressive surgery in spinal cord injury; hypothermia, therapeutic; stem cell therapy, spinal cord injury; thoracic spine injuries; thoraco-lumbar spine injuries
- spinal fixation techniques, instrumented 244
- sports injuries, traumatic brain injury 8–9  
 children 22–23
- high-impact 62  
 mild 50  
 spreading depolarization (SD) 84  
*see also* cortical spreading depression (CSD)
- STASCIS (Surgical Trial in Acute Spinal Cord Injury Study) 246
- stem cell(s)  
 multipotent 281  
 mesenchymal stromal cells 283  
 neural stem cells 282  
 pluripotent 281  
 embryonic stem cells 282  
 induced 286  
 totipotent 281
- stem cell therapy, spinal cord injury 280, 281–289  
 biocompatible implant combination 288–289  
 combined therapy 288–289  
 embryonic stem cells 282  
 induced pluripotent stem cells 286  
 interventions 289  
 mesenchymal stromal cells 284, 283–284, 285, 288  
 neural stem cells 282–283  
 olfactory ensheathing glia 285  
 Schwann cells 285  
 SPIO nanoparticles for monitoring 286–288  
 stimulated macrophages 285–286  
 stepping, newborn movements 307
- stress 36
- stroke  
 constraint-induced movement therapy 182–184  
 cortical plasticity 187  
 function recovery 181–184  
 rehabilitation 183–184, 187
- subarachnoid hemorrhage, severe blast injury 33–34
- Subaxial Injury Classification (SLIC) 233, 233–234
- subcortical white matter, metabolism 61–62
- subdural hematoma, elderly people 12
- substance abuse, TBI 36
- superparamagnetic iron-oxide (SPIO) nanoparticles 286–288  
 mesenchymal stromal cell labeling 284, 288
- suppressor of cytokine signaling 3 (SOC3) 276
- survivors of TBI 2
- susceptibility weighted imaging (SWI) 55–56
- synapses, pruning 183
- synaptophysin 187
- systems biology 202

Cambridge University Press

978-1-107-53471-1 - Traumatic Brain and Spinal Cord Injury: Challenges and Developments

Edited by Cristina Morganti-Kossmann, Ramesh Raghupathi and Andrew Maas

Index

[More information](#)

## Index

- c-Tau biomarker 37
- temperature management in spinal cord injury
  - see also* hypothermia, therapeutic
  - temperature rise, TBI 314–315
- terrorist attacks 9
- tetraplegia, incomplete 236, 235–236
- thermal dilution flow probes 71
- thoracic spine injuries
  - animal models of spinal cord injury 256–257
  - kyphosis 237, 238
  - mini-transthoracic approach 239
  - stabilization 237–239
  - thoracoscopic approach 239
  - treatment 237–239
- Thoraco-Lumbar Injury Classification (TLIC) 234, 233–234
- thoraco-lumbar spine injuries 239
  - vertebral fractures
    - 3-column model of Denis 234
    - classification 234
    - Magerl–AO classification 234
- tight glucose control 95
  - children 99
- tissue injury 272
- tissue oxygenation 69–71
- toddlers 126–127
- tractography 59
- traffic-related injuries *see* road traffic injuries
- training therapy in spinal cord injury 294–296, 305–311
  - animal models 295–296
  - clinical trials 325–327
  - disadvantages 296
  - gait training 296
  - optimizing 310
  - use-dependent activity 295
- transforming growth factor  $\beta$  (TGF- $\beta$ ), microglial 156–157
- trauma
  - care 25, 27
  - see also* neurotrauma, low- and middle-income countries
- traumatic axonal injury
  - animal models 140, 267
  - impact-acceleration model 118
  - optic nerve injury model 115
- traumatic axonal injury (TAI) 38, 138–150
  - $\beta$ -amyloid precursor protein 147–148
  - animal models 139–143
  - childhood TBI 129
  - closed skull impact injury 141–142
  - controlled cortical impact 140
  - fluid percussion injury 141, 140–141
  - open skull impact/impulse injury 140–141
  - optic nerve stretch injury 142
  - rapid stretch injury in vivo 142–143
  - rotational-acceleration injury 139–140
- axolemma permeability 143–144
- axonal swellings 143
- calpains 148
- caspases 148
- chronic phase 139
- definition 138
- diffusion tensor imaging 58
- hypothermia treatment 149, 150
- imaging 54
- immunosuppressive drugs 149, 150
- ion homeostasis 144–145
- mechanisms 138–139
- microglial clusters 55
- microtubules 146–147
- myelin/myelination 145
- neurofilaments 145–146
- neuronal cell death 148
- pathobiology 143–148
- poloxamer 188 treatment 143–144
- progressive 55
- proteases 148
- TBI pathophysiology 55
- treatment 149, 148–150
- traumatic brain injury (TBI)
  - admission criteria 2
  - age in low- and middle-income countries 23
  - ageing society 11, 11–12
  - assault 9
  - biochemical pathways 103
  - causes 3, 4, 5
    - low- and middle-income countries 23–24
  - cellular event cascade 68
  - children
    - low- and middle-income countries 22–23
    - outcomes 92
    - prevention 9–10
  - classification 1–2, 33, 32–33, 34, 82
  - limitations 104
  - closed 32, 33
  - cognitive decline 3
  - community surveys 2
  - consequences 35–36
  - CT diagnosis limitations 104
  - definition 1–2, 18, 33, 32–33, 34
  - depression 36
  - diagnostic tools 104
  - economic costs 3, 103
  - low- and middle-income countries 26
  - elderly people, low- and middle-income countries 23
  - epidemiology 1–12, 103
  - epilepsy 35–36
  - falls 8, 11–12
  - India 21
  - low- and middle-income countries 27
  - Papua New Guinea 21
  - gender, low- and middle-income countries 23
  - high-income countries, burden 19
  - human cost 2–3
  - incidence 1, 2, 5, 20
  - injury pattern 114
  - microstructural integrity 58–59
  - morbidity 2
  - mortality 2, 3, 35, 82
  - occupational injuries 9
  - outcomes 2–3, 92
    - children 126
    - clinical interventions 205
    - low- and middle-income countries 25–26
    - management 105
  - pathobiology 103
  - pathophysiology 54–55, 67
  - penetrating 32, 33
  - personal protective equipment 38–39
  - prevalence 2
    - low- and middle-income countries 23
    - military personnel 31–32
  - prevention 3, 3–4
    - in children 9–10
    - legislation 10
    - low- and middle-income countries 26–27
    - strategy effectiveness 10
  - productivity loss 3
  - recreational injuries 8–9
  - referral patterns 2
  - screening in military personnel 34–35
  - self-harm 9
  - severity 2, 104
    - low- and middle-income countries 25
  - sleep disorders 36
  - stress 36
  - substance abuse 36
  - survivors 2
  - temperature rise 314–315
  - treatment
    - decompressive craniectomy 205–207

Index

traumatic brain injury (TBI) ( <i>cont.</i> ) erythropoietin 164, 210–212 future perspectives 205–212 trends 3 road traffic injuries 5–6 <i>see also</i> blast injury; falls; hypothermia, therapeutic; mild traumatic brain injury (mTBI); moderate traumatic brain injury (TBI); neurotrauma, low- and middle-income countries; road traffic injuries; severe traumatic brain injury (TBI) traxoprodil, clinical trials 172 treadmill training body-weight support 305, 308 clinical trials 326 manually assisted 308–309	robotic/robot-assisted 308–310 TROY signal transducing receptor 265 tumor necrosis factor (TNF) 161 tympanic membrane, blast injury 34, 37 ubiquitin C-terminal hydrolase L1 (UCH-L1) 108 vasogenic edema, cryogenic lesion rodent model 115 vasospasm, blast injury 38 vertebroplasty 239 violence assault 9 neurotrauma in low- and middle-income countries 23–24	war-related in India 21 visceral function, animal models of spinal cord injury 257–258 walking evaluation 256–257 recovery 326–327 rehabilitation goal 305 Wallerian degeneration 146 calpains microglia 274–275 oligodendrocyte apoptosis 266–267 war-related violence, India 21 Warrior Administered Retrospective Casualty Assessment Tool (WARCAT) 34 white matter injury, mechanisms 55 Wnts 264
---	---	--